FDA restricts Johnson & Johnson’s COVID-19 vaccine due to blood clot risk

- Advertisement -


WASHINGTON — US regulators on Thursday strictly limited who can receive Johnson & Johnson’s COVID-19 vaccine due to a rare but serious risk of blood clots.

- Advertisement -

The Food and Drug Administration said the shot should only be given to adults who cannot receive a different vaccine or specifically request J&J’s JNJ,
-1.91%
vaccine. US authorities for months have recommended that Americans starting their COVID-19 vaccinations use the Pfizer PFE,
-2.44%
or Moderna mRNA,
-8.40%
shots instead.

- Advertisement -

FDA officials said in a statement that they decided to restrict J&J’s vaccine after taking another look at data on the risk of life-threatening blood clots within two weeks of vaccination.

The decision is the latest restriction to hit J&J’s one-dose vaccine, which has long been overshadowed by the more effective two shots from Pfizer and Moderna.

- Advertisement -

In December, the Centers for Disease Control and Prevention recommended prioritizing the Moderna and Pfizer shots over J&J’s because of its safety issues. Previously US officials had treated all three vaccines similarly because they’d each been shown to offer strong protection.

But follow-up studies have consistently shown lower effectiveness for J&J’s vaccine. And while the blood clots seen with J&J’s shot are rare, officials say they’re still occurring.

,

Credit: www.marketwatch.com /

- Advertisement -

Stay on top - Get the daily news in your inbox

DMCA / Correction Notice

Recent Articles

Related Stories

Stay on top - Get the daily news in your inbox